Immix Biopharma
IMMX
9.49
-0.15
-1.56%
Immix Biopharma
US · IMMX
#3426 by market cap
Listed 2021
9.49
-0.15
-1.56%
Live - 5344 symbols - heartbeat 526s ago
· 2026-10-08 09:01
Pre-market
9.42
-0.78%
After-hours
9.49
0.00%
- Market cap
- 788.42M
- P/E (TTM)i
- -10.78
- P/Bi
- 3.44
- EPSi
- -0.89
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on IMMX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 259.34K | 205.70K | 1.23M | 4.02M | 7.41M | 11.38M | 13.70M |
| Research & development | 583.16K | 248.15K | 126.53K | 4.20M | 8.74M | 11.29M | 16.26M |
| Operating profit | -842.50K | -453.85K | -1.35M | -8.22M | -16.14M | -22.67M | -29.96M |
| Pretax profit | -952.26K | -1.13M | -24.38M | -8.22M | -15.57M | -21.66M | -29.40M |
| Tax | 20.55K | 17.55K | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net profit | -972.81K | -1.15M | -24.38M | -8.23M | -15.60M | -21.70M | -29.44M |
| Basic EPS | 0 | 0 | -7 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.12 | -0.13 | -6.64 | -0.59 | -0.89 | -0.76 | -0.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.71M | 2.75M | 3.08M | 5.17M | 4.82M | 7.12M |
| Research & development | 1.98M | 3.97M | 4.58M | 5.73M | 5.98M | 5.33M |
| Operating profit | -4.68M | -6.72M | -7.66M | -10.89M | -10.80M | -12.46M |
| Pretax profit | -4.53M | -6.61M | -7.58M | -10.68M | -10.09M | -11.54M |
| Tax | 9.82K | 8.91K | 7.72K | 11.27K | 0 | 14.32K |
| Net profit | -4.54M | -6.62M | -7.59M | -10.69M | -10.09M | -11.56M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.15 | -0.22 | -0.24 | -0.28 | -0.18 | -0.18 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 933.26K | 532.24K | 18.19M | 14.90M | 19.79M | 20.20M | 101.24M |
| Cash & ST investments | 734.01K | 391.09K | 17.64M | 13.44M | 17.51M | 17.68M | 100.41M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 942.94K | 539.60K | 18.19M | 14.91M | 19.93M | 22.95M | 104.84M |
| Total current liabilities | 4.59M | 5.27M | 202.04K | 1.27M | 3.72M | 8.69M | 10.11M |
| Short-term debt | 4.10M | 4.10M | 50.00K | -- | -- | 65.22K | 139.34K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 4,589,302.00 | 5,270,181.00 | 202,039.00 | 1,748,296.00 | 3,721,783.00 | 9,696,669.00 | 11,044,171.00 |
| Total equity | -3.65M | -4.73M | 17.99M | 13.16M | 16.20M | 13.25M | 93.80M |
| Retained earnings | -4.22M | -5.37M | -29.76M | -37.99M | -53.41M | -75.02M | -104.46M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 16.78M | 12.33M | 16.58M | 101.24M | 92.27M | 233.79M |
| Cash & ST investments | 15.92M | 11.64M | 15.95M | 100.41M | 90.58M | 232.11M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 19.89M | 15.64M | 20.08M | 104.84M | 95.82M | 239.11M |
| Total current liabilities | 9.31M | 10.01M | 10.85M | 10.11M | 10.54M | 9.30M |
| Short-term debt | 67.82K | 70.47K | 141.28K | 139.34K | 125.39K | 111.11K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 10,298,487.00 | 10,982,073.00 | 11,815,634.00 | 11,044,171.00 | 11,452,001.00 | 10,192,343.00 |
| Total equity | 9.59M | 4.65M | 8.26M | 93.80M | 84.36M | 228.92M |
| Retained earnings | -79.57M | -86.19M | -93.78M | -104.46M | -114.55M | -126.11M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -790.03K | -404.69K | -1.59M | -7.41M | -11.37M | -14.60M | -23.93M |
| Depreciation & amortization | 1.08K | 2.32K | 2.47K | 2.14K | 5.47K | 115.39K | 364.50K |
| Free cash flow | -797.34K | -404.69K | -1.59M | -7.41M | -11.42M | -15.77M | -24.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 18.65M | 3.29M | 15.70M | 15.95M | 107.39M |
| Ending cash balance | 734.01K | 391.09K | 17.64M | 13.44M | 17.51M | 17.68M | 93.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -1.69M | -5.31M | -5.91M | -11.03M | -9.83M | -11.74M |
| Depreciation & amortization | 59.18K | 79.84K | 134.86K | 90.63K | 130.77K | 130.88K |
| Free cash flow | -1.75M | -5.44M | -6.28M | -11.19M | -9.86M | -11.76M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 10.77M | 95.51M | -- | -- |
| Ending cash balance | 15.92M | 11.64M | 15.95M | 93.93M | 79.25M | 225.49M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -367.80 | -52.84 | -104.35 | -145.76 | -55.00 |
| ROA %i | -103.17 | -63.81 | -260.35 | -49.73 | -88.57 | -100.83 | -46.07 |
| ROIC %i | -- | -- | -278.61 | -52.84 | -107.23 | -140.67 | -54.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -145.15 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.20 | 0.10 | 90.01 | 11.70 | 5.32 | 2.33 | 10.01 |
| Quick ratioi | 0.20 | 0.10 | 87.46 | 10.75 | 5.02 | 2.26 | 9.93 |
| Debt / assetsi | 434.81 | 759.83 | 0.27 | -- | 0.00 | 4.68 | 1.02 |
| LT debt / equityi | -- | -- | -- | -- | -- | 7.62 | 1.00 |
| Interest coveragei | -7.66 | -10.08 | -134.54 | -16,537.12 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -111.42 | -162.04 | -182.55 | -55.00 | -74.47 | -34.18 |
| ROA %i | -77.05 | -104.01 | -104.21 | -46.07 | -60.47 | -31.34 |
| ROIC %i | -108.75 | -154.15 | -171.03 | -54.68 | -74.24 | -34.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.80 | 1.23 | 1.53 | 10.01 | 8.76 | 25.13 |
| Quick ratioi | 1.71 | 1.16 | 1.47 | 9.93 | 8.59 | 24.95 |
| Debt / assetsi | 5.32 | 6.67 | 5.51 | 1.02 | 1.08 | 0.42 |
| LT debt / equityi | 10.33 | 20.90 | 11.68 | 1.00 | 1.08 | 0.39 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 09:01:25 · For reference only, not investment advice and not tailored to your situation.